tbuckley/cabot-search huggingface dataset:
Identification of serum proteome signatures of male breast cancer
Authors: E. Zografos, A. Anagnostopoulos, A. Papadopoulou, E. Legaki, F. Zagouri, E. Marinos, G. Tsangaris, M. Gazouli
Journal: Annals of Oncology (2019)

Background: Male breast cancer (MBC) is a rare entity accounting for less than 1% of all malignancies in men. To date, little emphasis has been placed on the elucidation of serum protein alterations in male breast carcinogenesis, even though serum represents an attractive, non-invasive source for biomarker discovery. Methods: In the present work, we employed two-dimensional gel electrophoresis (2-DE) separation and matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry analysis to detect differences in serum protein expression between MBC patients and healthy controls. The differential expression of selected proteins was confirmed by Western Blot analysis or Enzyme Linked Immunosorbent Assay (ELISA). Functional relationships analysis of the differentially expressed proteins was performed using the STRING v.10 database. The PANTHER database was used to reveal the molecular function and signaling pathway associated with each identified protein. Results: A panel of differentially expressed serum proteins has been identified in MBC patients compared to controls, including proteins involved in the regulation of the cell cycle (ANCHR, CDC7, PDIP2), in mitochondrial function (ALDH2, TFB1M, NDUAB), in lipid metabolism and transport (APOA1, APOA4, APOE, APOH), in apoptosis and immune response (CD5L, CLUS, CCL14, LFTY2), in transcription (SSX3, STAT3, ZN223, ZN266, ZN273, ZN624, ZKSC7, RNZ2), in invasion and metastasis (FETUA, K1C10, K1C9, VTNC, AX2R, RAB37), in estrogen synthesis (CYP19A1) and with other diverse biological roles (BCAT1, CRYAB, CERU, ERMP1, MLH3, PRP18, RET4, SAMP, SYT1). Concurrently, several proteins were detected only in the MBC group (ARPC4, MP2K4, ENC1, MMP27). Conclusions: These findings provide new insight into the distinct clinicopathological features of MBC and indicate that select serum proteomic biomarkers might help improve MBC management. Legal entity responsible for the study: Department of Basic Medical Sciences, Laboratory of Biology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Funding: Has not received any funding. Disclosure: F. Zagouri: Research and advisory grants: Novartis, Lilly, Pfizer. All other authors have declared no conflicts of interest.
Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class
Authors: Jean Kim, Tiffany Farchione, Andrew Potter, Qi Chen, Robert Temple
Journal: New England Journal of Medicine (2019)

Interview with Dr. Roy Perlis on esketamine as an option for treatment-resistant depression. (08:16)Download The FDA has approved esketamine, the first antidepressant in a new class, for treatment-resistant depression. The agency weighed the drug's rapid onset of effect against its abuse potential, which led to a Risk Evaluation and Mitigation Strategy.
A Unifying Concept for the Quantitative Assessment of Secondary Mitral Regurgitation
Authors: Philipp E. Bartko, Henrike Arfsten, Gregor Heitzinger, Noemi Pavo, Aurel Toma, Guido Strunk, Christian Hengstenberg, Martin Hülsmann, Georg Goliasch
Journal: Journal of the American College of Cardiology (2019)
EVALUATION OF PREDICTORS FACTORS OF FAILURE IN ENDOSCOPIC BILIARY DRAINAGE IN MALIGNANT HILAR BILIARY STRICTURE
Authors: L Haendchen Bento, E Mendonça, B Costa Martins, R Jureidini, T Bacchella, A Safatle-Ribeiro, U Ribeiro, F Maluf-Filho
Journal: Endoscopy (2019)

To evaluate the clinical success of biliary drainage by ERCP in patients with primary or secondary malignant hilar biliary stricture and to analyze the predictors factors of failure.
A Student Reflection on Doctoring With Confidence
Authors: Juan N. Lessing, Mary E. Lacy
Journal: Annals of Internal Medicine (2019)

Letters21 May 2019A Student Reflection on Doctoring With ConfidenceJuan N. Lessing, MD and Mary E. Lacy, MDJuan N. Lessing, MDUniversity of Colorado School of Medicine, Denver, Colorado (J.N.L.)Search for more papers by this author and Mary E. Lacy, MDUniversity of New Mexico School of Medicine, Albuquerque, New Mexico (M.E.L.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0121 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Treadway's commentary (1) opened our eyes to the possibility that we are unwittingly treating learners differently on the basis of gender. We also agree with the author that discussing our own uncertainty among ourselves is as important as doing so with our patients. Further, as medical educators who have told learners countless times to present with confidence, we became curious how these learners might be perceiving and interpreting this feedback. The burden of clarity in setting expectations falls on us as educators, and—as Treadway makes clear—we have been missing the mark. For example, an intern who recently ...References1. Treadway N. A student reflection on doctoring with confidence: mind the gap. Ann Intern Med. 2018;169:564-5. [PMID: 30208402]. doi:10.7326/M18-0865 LinkGoogle Scholar2. Brown PC, Roediger HL, McDaniel MA. Make It Stick The Science of Successful Learning. Cambridge, MA: Harvard Univ Pr; 2014. Google Scholar3. Lemov D. Teach Like a Champion: 49 Techniques That Put Students on the Path to College. San Francisco: Jossey-Bass; 2010. Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Colorado School of Medicine, Denver, Colorado (J.N.L.)University of New Mexico School of Medicine, Albuquerque, New Mexico (M.E.L.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L19-0121. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoA Student Reflection on Doctoring With Confidence: Mind the Gap Nicole Treadway A Student Reflection on Doctoring With Confidence Nicole Treadway A Student Reflection on Doctoring With Confidence Richard L. Kravitz A Student Reflection on Doctoring With Confidence John E. Coda Metrics 21 May 2019Volume 170, Issue 10Page: 739KeywordsDisclosureFallsForecastingMotivationReasoningSexual identity ePublished: 21 May 2019 Issue Published: 21 May 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Abstract 16367: Does Left Atrial Appendage Exclusion Using an Epicardial System Reduce Systemic Blood Pressures? - The Dawn of a New Frontier
Authors: Dhanunjaya Lakkireddy, Johnson Rajasingh, Sandia Iskandar, Rizwan Afzal, Matthew Earnest, Donita Atkins, Sudharani Bommana, Luigi Di Biase, Sacha Salzberg, Basel Ramlawi, Rakesh Gopinathannair, Andrea Natale, James L Cox
Journal: Circulation (2016)

Introduction: Hypertension causes significant systemic and cardiovascular morbidity and mortality. While pharmacologic agents are helpful, renovascular interventions had mixed results. LAA is a uni...
Traitement endoscopique par clip Ovesco des perforations duodénales post echo-endoscopie
Authors: H Elbacha, S Leblanc, B Bordacahar, B Brieau, JC Duchmann, M Barret, F Prat
Journal: Endoscopy (2019)

La perforation duodénale est une complication rare mais potentiellement sévère de l'échoendoscopie. La prise en charge est souvent chirurgicale. L'apport de l'insuflation en CO2 et l'apparition des clips Ovesco permettent d'envisager un traitement endoscopique des perforations. Le but de notre étude est de rapporter les caracteristiques des perforations duodénales post echoendoscopie et l'efficacité de leur traitement endoscopique.
THE MANAGEMENT OF GASTRIC MALT LYMPHOMA
Authors: SH Lee, MC Kim, MK Kang, JH Cho, SB Kim, KH Kim, KO Kim, BI Jang, TN Kim
Journal: Endoscopy (2019)

Helocibacter pylori (H.pylori) eradication is an effective treatment in H.pylori-positive mucosa-associated lymphoid tissue (MALT) lymphoma. However, the complete remission (CR) rates after H.pylori eradication in H.pylori-negative MALT lymphoma is very low and the treatment strategy remains controversial. We investigated the effectiveness of each treatment option for H.pylori-negative MALT lymphoma and H.pylori-positive MALT lymphoma with treatment failure after H.pylori eradication.
Immune cell dynamics induced by a single dose of pembrolizumab as revealed by single-cell RNA profiling
Authors: H. Vos, A. Bassez, J. Qian, G. Floris, I. Nevelsteen, K. Lambein, P. Neven, H. Wildiers, D. Lambrechts, A. Smeets
Journal: Annals of Oncology (2019)

Background: To improve our understanding of the molecular mechanisms underlying response to immune checkpoint inhibition, we monitored dynamic changes within the tumour microenvironment exposed to immune checkpoint inhibition by single-cell RNA sequencing (scRNA-seq). Methods: In a window-of-opportunity setting, fresh tumor tissue was collected from breast cancer patients before and 10 days after a single dose of 200 mg Pembrolizumab monotherapy. Hematoxylin-eosin (H&E) staining to determine tumor infiltrating lymphocytes (TILs) and scRNA-seq was performed on fixed and fresh tumor tissue, respectively. Single cell suspensions were subjected to 10X Genomics scRNA- and T-cell receptor-sequencing using the Chromium Single Cell 5' kit on an Illumina NovaSeq. Expression matrices were generated using CellRanger and analyzed by Seurat. Dimensionality reduction was applied by PCA. Results: Currently, 7 paired tumor samples have been analyzed. All were ER/PR-negative IDA, of which 3 were pre-treated with neo-adjuvant chemotherapy. On H&E slide, there were no notable differences in TILs comparing biopsies before versus after Pembro. By scRNA-seq, we did observe several prominent changes. First, there was a decrease in cancer cells versus an increase in immune cells after Pembro. Second, the increase in T-cells was due to an increased prevalence of exhausted CD4+ and CD8+ cytotoxic cells, as well as regulatory T-cells, which were all positive for PD1 expression. Cytolytic activity in these T-cell subpopulations also increased significantly, and this was accompanied by a specific increase in TCR clonotypes in these. Finally, in 3 out of 7 pairs such changes in T-cells were not detectable. In these post-treatment samples, a decrease in expression of MHC class 1 genes was observed specifically in cancer cells. Conclusions: Our data suggest that scRNA-seq creates accurate maps of the tumor micro-environment and is capable of monitoring dynamic changes already induced by a single dose of immunotherapy. Particularly, in 4/7 patients changes in T-cells reactivity reminiscent of a clinical response to Pembrolizumab were noted. Other patients failed to display such reactivity presumably due to a failure in presenting neo-epitopes by MHC class 1 genes. Clinical trial identification: NCT03197389. Legal entity responsible for the study: University Hospitals Leuven. Funding: Investigator initiated study MSD Kom op Tegen Kanker Fonds Nadine de Beauffort VIB VIB Grand Challenge. Disclosure: All authors have declared no conflicts of interest.
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Authors: Dung T. Le, Vincent J. Picozzi, Andrew H. Ko, Zev A. Wainberg, Hedy Kindler, Andrea Wang-Gillam, Paul Oberstein, Michael A. Morse, Herbert J. Zeh, Colin Weekes, Tony Reid, Erkut Borazanci, Todd Crocenzi, Noelle K. LoConte, Benjamin Musher, Dan Laheru, Aimee Murphy, Chan Whiting, Nitya Nair, Amanda Enstrom, Sandy Ferber, Dirk G. Brockstedt, Elizabeth M. Jaffee
Journal: Clinical Cancer Research (2019)

Limited options exist for patients with advanced pancreatic cancer progressing after 1 or more lines of therapy. A phase II study in patients with previously treated metastatic pancreatic cancer showed that combining GVAX pancreas (granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor cells) with cyclophosphamide (Cy) and CRS-207 (live, attenuated Listeria monocytogenes expressing mesothelin) resulted in median overall survival (OS) of 6.1 months, which compares favorably with historical OS achieved with chemotherapy. In the current study, we compared Cy/GVAX + CRS-207, CRS-207 alone, and standard chemotherapy in a three-arm, randomized, controlled phase IIb trial.Patients with previously treated metastatic pancreatic adenocarcinoma were randomized 1:1:1 to receive Cy/GVAX + CRS-207 (arm A), CRS-207 (arm B), or physician's choice of single-agent chemotherapy (arm C). The primary cohort included patients who had failed ≥2 prior lines of therapy, including gemcitabine. The primary objective compared OS between arms A and C in the primary cohort. The second-line cohort included patients who had received 1 prior line of therapy. Additional objectives included OS between all treatment arms, safety, and tumor responses.The study did not meet its primary efficacy endpoint. At the final study analysis, median OS [95% confidence interval (CI)] in the primary cohort (N = 213) was 3.7 (2.9-5.3), 5.4 (4.2-6.4), and 4.6 (4.2-5.7) months in arms A, B, and C, respectively, showing no significant difference between arm A and arm C [P = not significant (NS), HR = 1.17; 95% CI, 0.84-1.64]. The most frequently reported adverse events in all treatment groups were chills, pyrexia, fatigue, and nausea. No treatment-related deaths occurred.The combination of Cy/GVAX + CRS-207 did not improve survival over chemotherapy. (ClinicalTrials.gov ID: NCT02004262)See related commentary by Salas-Benito et al., p. 5435.
Does soccer headgear reduce the incidence of sport-related concussion? A cluster, randomised controlled trial of adolescent athletes
Authors: Timothy McGuine, Eric Post, Adam Yakuro Pfaller, Scott Hetzel, Allison Schwarz, M Alison Brooks, Stephanie A Kliethermes
Journal: British Journal of Sports Medicine (2019)

Background There have been no large randomised controlled trials to determine whether soccer headgear reduces the incidence or severity of sport-related concussion (SRC) in US high school athletes. Objective We aimed to determine whether headgear reduces the incidence or severity (days out from soccer) of SRCs in soccer players. Methods 2766 participants (67% female, age 15.6±1.2) (who undertook 3050 participant years) participated in this cluster randomised trial. Athletes in the headgear (HG) group wore headgear during the season, while those in the no headgear (NoHG) group did not. Staff recorded SRC and non-SRC injuries and soccer exposures. Multivariate Cox proportional hazards models were used to examine time-to-SRC between groups, while severity was compared with a Wilcoxon rank-sum test. Results 130 participants (5.3% female, 2.2% male) sustained an SRC. The incidence of SRC was not different between the HG and NoHG groups for males (HR: 2.00 (0.63–6.43) p=0.242) and females (HR: 0.86 (0.54–1.36) p=0.520). Days lost from SRC were not different (p=0.583) between the HG group (13.5 (11.0–018.8) days) and the NoHG group (13.0 (9.0–18.8) days). Conclusions Soccer headgear did not reduce the incidence or severity of SRC in high school soccer players. Trial registration number NCT02850926 .
Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in Over 140,000 European Descendants
Authors: Lang Wu, Jifeng Wang, Qiuyin Cai, Taylor B. Cavazos, Nima C. Emami, Jirong Long, Xiao-Ou Shu, Yingchang Lu, Xingyi Guo, Joshua A. Bauer, Bogdan Pasaniuc, Kathryn L. Penney, Matthew L. Freedman, Zsofia Kote-Jarai, John S. Witte, Christopher A. Haiman, Rosalind A. Eeles, Wei Zheng
Journal: Cancer Research (2019)

Abstract Genome-wide association study–identified prostate cancer risk variants explain only a relatively small fraction of its familial relative risk, and the genes responsible for many of these identified associations remain unknown. To discover novel prostate cancer genetic loci and possible causal genes at previously identified risk loci, we performed a transcriptome-wide association study in 79,194 cases and 61,112 controls of European ancestry. Using data from the Genotype-Tissue Expression Project, we established genetic models to predict gene expression across the transcriptome for both prostate models and cross-tissue models and evaluated model performance using two independent datasets. We identified significant associations for 137 genes at P &amp;lt; 2.61 × 10−6, a Bonferroni-corrected threshold, including nine genes that remained significant at P &amp;lt; 2.61 × 10−6 after adjusting for all known prostate cancer risk variants in nearby regions. Of the 128 remaining associated genes, 94 have not yet been reported as potential target genes at known loci. We silenced 14 genes and many showed a consistent effect on viability and colony-forming efficiency in three cell lines. Our study provides substantial new information to advance our understanding of prostate cancer genetics and biology. Significance: This study identifies novel prostate cancer genetic loci and possible causal genes, advancing our understanding of the molecular mechanisms that drive prostate cancer.
Laterality and Stimulation Bias in Meta-analysis of Placebo Responses
Authors: Clas Linnman, Leon Morales-Quezada
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation
Authors: Anil Pooran, Grant Theron, Lynn Zijenah, Duncan Chanda, Petra Clowes, Lawrence Mwenge, Farirai Mutenherwa, Paul Lecesse, John Metcalfe, Hojoon Sohn, Michael Hoelscher, Alex Pym, Jonny Peter, David Dowdy, Keertan Dheda
Journal: The Lancet Global Health (2019)

Rapid on-site diagnosis facilitates tuberculosis control. Performing Xpert MTB/RIF (Xpert) at point of care is feasible, even when performed by minimally trained health-care workers, and when compared with point-of-care smear microscopy, reduces time to diagnosis and pretreatment loss to follow-up. However, whether Xpert is cost-effective at point of care remains unclear.We empirically collected cost (US$, 2014) and clinical outcome data from participants presenting to primary health-care facilities in four African countries (South Africa, Zambia, Zimbabwe, and Tanzania) during the TB-NEAT trial. Costs were determined using an bottom-up ingredients approach. Effectiveness measures from the trial included number of cases diagnosed, initiated on treatment, and completing treatment. The primary outcome was the incremental cost-effectiveness of point-of-care Xpert relative to smear microscopy. The study was performed from the perspective of the health-care provider.Using data from 1502 patients, we calculated that the mean Xpert unit cost was lower when performed at a centralised laboratory (Lab Xpert) rather than at point of care ($23·00 [95% CI 22·12-23·88] vs $28·03 [26·19-29·87]). Per 1000 patients screened, and relative to smear microscopy, point-of-care Xpert cost an additional $35 529 (27 054-40 025) and was associated with an additional 24·3 treatment initiations ([-20·0 to 68·5]; $1464 per treatment), 63·4 same-day treatment initiations ([27·3-99·4]; $511 per same-day treatment), and 29·4 treatment completions ([-6·9 to 65·6]; $1211 per completion). Xpert costs were most sensitive to test volume, whereas incremental outcomes were most sensitive to the number of patients initiating and completing treatment. The probability of point-of-care Xpert being cost-effective was 90% at a willingness to pay of $3820 per treatment completion.In southern Africa, although point-of-care Xpert unit cost is higher than Lab Xpert, it is likely to offer good value for money relative to smear microscopy. With the current availability of point-of-care nucleic acid amplification platforms (eg, Xpert Edge), these data inform much needed investment and resource allocation strategies in tuberculosis endemic settings.European Union European and Developing Countries Clinical Trials Partnership.
First report the findings: genuine balance when reporting CTE
Authors: Stephen T Casper, Janet Golden, Naomi Oreskes, Mark Largent, Daniel S Goldberg, Grant Gillett, Sean Philpott-Jones, Tiago Moreira, Jaipreet Virdi, Todd Meyers, Daniel Morrison, Julia E Rodriguez, Joseph M Gabriel, Jacob Steere-Williams, Ryan Ross, Jay M Smith, Jesse F Ballenger, Geoff Bil, Yumiko Kawaguchi, Erika Dyck, Felicity Callard, Francisco Ortega, Sherryl Kleinman, Michael Brown
Journal: The Lancet Neurology (2019)
Drainage biliaire des sténoses malignes: Résultats et survie des patients
Authors: A maktoub, N Lahmidani, FZ Hamdoun, A Lamine, M Lahlali, H Abid, M Elyoussfi, DA Benajah, M Elabkari, SA Ibrahimi
Journal: Endoscopy (2019)

Le développement de l'endoscopie interventionnelle a produit un bouleversement profond dans le traitement des sténoses malignes des voies biliaires en palliatif ou en bridge vers la chirurgie. Le but de notre travail est de rapporter l'expérience de notre service dans le traitement endoscopique des sténoses biliaires malignes.
Blood Viscosity and its Relevance to the Diagnosis and Management of Pulmonary Hypertension
Authors: Aleksander Kempny, Konstantinos Dimopoulos, Alain Fraisse, Gerhard-Paul Diller, Laura C. Price, Isma Rafiq, Colm McCabe, Michael A. Gatzoulis, Stephen John Wort
Journal: Journal of the American College of Cardiology (2019)

Pulmonary vascular resistance (PVR) is an essential parameter assessed during cardiac catheterization. It is used to assess response to targeted pulmonary hypertension (PH) therapy; determine the possibility of surgery, such as closure of intracardiac shunt or heart transplantation; and according to
Досягнення гепатології. За матеріалами 22-го Європейського гастроентерологічного тижня (18–22 жовтня 2014 р.)
Authors: Yu.M. Stepanov, V.B. Yahmur
Journal: GASTROENTEROLOGY (2020)

У статті висвітлюються останні досягнення у веденні хворих iз патологією печінки різної етіології. Використання препаратів прямої противірусної дії, а також безінтерферонових режимів терапії дозволяє досягти стійкої вірусологічної відповіді у більшості пацієнтів, що інфіковані вірусом гепатиту С. Наведено нові дані про застосування статинів, інгібіторів протонної помпи, антибіотиків при цирозі та портальній гіпертензії. Проведено огляд принципово нового типу лікування первинного біліарного цирозу, який заснований на стимуляції фарнезоїдних Х-рецепторів. Наведені клінічні дослідження альфа-помпи, яка покращує якість життя хворих з асцитом, а також принципово нового пристрою для екстракорпоральної детоксикації.